CAM.L

Camellia Plc
Camellia PLC - Update on BF&M Transaction
28th June 2024, 12:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3659U
Camellia PLC
28 June 2024
 

28 June 2024

Camellia Plc

(the "Company" or the "Group")

 

Update on BF&M Transaction and change of name of Nominated Adviser

 

Update on BF&M Transaction

 

Further to the most recent update on the disposal of the Company's 36.9% shareholding in BF&M to Argus Group provided in our trading update on 6 June 2024, BF&M Limited ("BF&M") and Argus Group Holdings Limited ("Argus") announced today that the two companies plan to amalgamate (pursuant to Bermuda law), subject to receipt of appropriate shareholder and regulatory approvals (the "Amalgamation"). 

 

This announcement by BF&M and Argus establishes a way forward for regulatory approval of the sale of Camellia's holding of BF&M shares to Argus (the "Sale").  The Amalgamation is expected to take place after the completion of the Sale and special general meetings of BF&M and Argus. As previously announced, we expect the completion of the Sale will take place in the latter part of 2024.

 

To facilitate the timely completion of the Sale and the Amalgamation, Camellia and Argus have agreed that up to $50 million of the agreed $100 million consideration payable to Camellia for the BF&M shares may be deferred in the form of interest-bearing loan notes with a maximum one year term.  The Sale is conditional on regulatory approvals and Argus financing.  Any loan notes issued will be secured by a pledge over the shares of the buyer and a guarantee from Argus prior to the Amalgamation and, following completion of the Amalgamation, guaranteed by BF&M, the ultimate parent company of the amalgamated entity.  If any of the consideration is deferred, Argus will be incentivised to pay down the loan quickly. The Company will provide further updates as appropriate.

 

Change of name of Nominated Advisor

 

The Company announces that its Nominated Adviser and Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

 

 

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

 

Enquiries

 

Camellia Plc                                                                        01622 746655

Byron Coombs, Chief Executive Officer

Oliver Capon, Chief Financial Officer

 

Panmure Liberum                                                              020 7886 2500

Nominated Adviser and Broker

Emma Earl

Rupert Dearden

 

H/Advisors Maitland 

PR

William Clutterbuck                                                             07785 292617

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDEANKPAFNLEEA]]>
TwitterFacebookLinkedIn